The ccd toxin-antitoxin module from the Escherichia coli F plasmid has a homologue on the Vibrio fischeri integron. The homologue of the toxin (CcdB Vfi ) was crystallized in two different crystal forms. The first form belongs to space group I23 or I2 1 3, with unit-cell parameter a = 84.5 Å , and diffracts to 1.5 Å resolution. The second crystal form belongs to space group C2, with unitcell parameters a = 58.5, b = 43.6, c = 37.5 Å , = 110.0 , and diffracts to 1.7 Å resolution. The complex of CcdB Vfi with the GyrA14 Vfi fragment of V. fischeri gyrase crystallizes in space group P2 1 2 1 2 1 , with unit-cell parameters a = 53.5, b = 94.6, c = 58.1 Å , and diffracts to 2.2 Å resolution. The corresponding mixed complex with E. coli GyrA14 Ec crystallizes in space group C2, with unit-cell parameters a = 130.1, b = 90.8, c = 58.1 Å , = 102.6 , and diffracts to 1.95 Å . Finally, a complex between CcdB Vfi and part of the F-plasmid antitoxin CcdA F crystallizes in space group P2 1 2 1 2 1 , with unit-cell parameters a = 46.9, b = 62.6, c = 82.0 Å , and diffracts to 1.9 Å resolution. # 2007 International Union of Crystallography All rights reserved crystallization communications Acta Cryst. (2007). F63, 356-360 De Jonge et al. CcdB 357 Figure 1
Introduction
Toxin-antitoxin modules (TA systems) were originally discovered on low-copy-number plasmids, where their function is to stabilize the plasmid on which they are located . TA modules are operons that contain two genes: one encoding a toxin and one encoding an antitoxin that neutralizes the toxin. The essential key to the functionality of these systems is the difference in stability and in vivo half-life of the two proteins (Dao-Thi et al., 2000; Van Melderen et al., 1994) . While the toxin is a stable protein with a long in vivo halflife, the antitoxin is relatively unstable and is targeted by specific proteases, reducing its in vivo half-life. Upon cell division, each daughter cell will inherit some of the toxin-antitoxin complexes from the cytoplasm. When a daughter cell does not inherit a copy of the plasmid, synthesis of the antitoxin is no longer possible. Antitoxin degradation will subsequently lead to liberation of the toxin. The toxin can then poison its target, leading to cell death. To date, two targets of TA toxins are known: the ccd and parDE modules target gyrase, while the more abundant relBE, mazEF, higBA and yoeb/ yefm modules cut mRNA (for recent reviews, see Buts et al., 2005; Gerdes et al., 2005; Condon, 2006) .
Ccd was the first TA module to be discovered and is located on the F-plasmid . The antitoxin is called CcdA and the toxin CcdB. The target of the toxin is the A subunit of DNA gyrase, an essential topoisomerase of the bacterial cell (Bernard & Couturier, 1992) . The crystal structures of the CcdB dimer and of a complex between CcdB and a relevant Escherichia coli gyrase fragment (GyrA14 Ec ) are known (Loris et al., 1999; Dao-Thi et al., 2005) . In the latter structure an important interaction is observed between Trp99 of CcdB and Arg462 of gyrase. This Trp99 is crucial for the poisoning activity of the CcdB, as proven by site-specific mutagenesis (Bahassi et al., 1995) .
Recently, TA modules were found to be abundant on bacterial and archaeal chromosomes (Pandey & Gerdes, 2005) . Although their function is obvious on plasmids, the role of chromosomal TA systems remains highly debated Gerdes et al., 2005; Engelberg-Kulka et al., 2006) . While some authors think they are involved in a kind of altruistic cell death under conditions of nutrient stress (Aizenman et al., 1996) , most authors tend to believe they are stress-induced regulators that bring the cell into a kind of metabolic stasis (Christensen et al., 2001) . Recent evidence shows that TA systems also play a role in the emergence of persister cells (a subpopulation of the cells that are in a specific metabolic state that is temporarily not susceptible to antibiotics; Keren et al., 2004; Lewis, 2005; Vazquez-Laslop et al., 2006) .
The ccd family, although the smallest of the TA families (Pandey & Gerdes, 2005) , also has several chromosomal homologues (Wilbaux et al., 2007) . One of the most remarkable of these is present on an integron of the Vibrio fischeri chromosome (Rowe-Magnus et al., 2003) . Here, the essential Trp99 in the toxin is not conserved but is substituted by Thr103 (see Fig. 1 ); its interaction partner on gyrase, Arg462, is conserved in most gyrases, including that of V. fischeri (see Fig. 1 ). Mutation of Arg462 to Cys in E. coli gyrase provides full protection against the toxic activity of F-plasmid CcdB (Bernard & Couturier, 1992) . How Thr103 of V. fischeri CcdB Vfi can take over the function of the Trp99 in F-plasmid CcdB F is unclear.
Here, we report the crystallization of CcdB Vfi as well as the crystallization of a complex of CcdB Vfi with the 36-amino-acid C-terminal half of the antitoxin from the F-plasmid (CcdA F37-72 ) and the crystallization of the complexes of CcdB Vfi with a relevant part of the gyrases (amino acids 362-493) from V. fischeri (GyrA14 Vfi ) and E. coli (GyrA14 Ec ). This is the first chromosomal member of the CcdB toxin family that has been expressed, purified and crystallized.
Materials and methods

Cloning, expression and purification
The ccdB Vfi gene was amplified by the polymerase chain reaction (PCR) using plasmid p1400 (Rowe-Magnus et al., 2003) as a template and using the following primers: 5 0 -EcoRIccdBVfi (5 0 -TTGTGA-ATTCTATGTCTCAATTTACGCTATAT-3 0 ) and 3 0 -PstIccdBVfi (5 0 -AGTCTCTGCAGTTTAAATGCCAGTGAT-3 0 ). The PCR product was cloned into the TOPO-XL vector (Invitrogen). The resulting plasmid was sequenced and then digested by EcoRI and PstI. The fragment containing ccdB Vfi was inserted into a pKK223-3 vector opened by the same enzymes.
E. coli strain B462 harbouring the pKK223-3 plasmid with the gene for CcdB Vfi was grown in 2ÂTY medium at 310 K until an OD 600 nm between 0.6 and 0.8 was reached. The cells were then induced by adding 1 mM isopropyl -d-thiogalactosidase (IPTG). After overnight incubation, the cells were harvested by centrifugation and subsequently resuspended in 20 mM Tris pH 7.0, 1 mM EDTA, 0.1 mg ml À1 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) and 1 g ml À1 leupeptin. Cells were broken at 277 K by passing the cells through a cell cracker and cell debris was removed by centrifugation (30 min, 12 000g). The pH of the supernatant was adjusted to 7.0 with diluted HCl. The supernatant was subsequently diluted with water to lower the conductivity to 1 mS cm À1 prior to loading onto a Source 30Q column (Amersham Biosciences, Uppsala, Sweden). This column was eluted with a ten column-volume linear gradient of 0-0.5 M NaCl. The CcdB Vfi -containing fractions were pooled and concentrated with a 0.5 kDa cutoff Vivaspin concentrator (Vivascience, Germany) prior to loading onto a Superdex 75 (16/90) size-exclusion column (run in 20 mM Tris pH 7.0, 1 mM EDTA, 150 mM NaCl). The eluted fractions containing CcdB Vfi showed essentially a single band of the correct molecular weight when analysed on SDS-PAGE.
GyrA14 Ec was expressed and purified as described by Dao-Thi et al. (2004) . The gyrA14 Vfi fragment was amplified by PCR from genomic DNA from V. fischeri CIP103206T (kindly provided by Didier Mazel, Institut Pasteur, France) using the following primers: 5 0 -CCCCATATGACTCGCCGTACTATTTTTGAATTAC-3 0 and 5 0 -CCCGGATCCTTAGCTTGCAAGAATATGCATTAGCTC-3 0 . The amplified fragment was digested with NdeI and BamHI and ligated in plasmid pET15b (Novagen), which was digested with the same restriction enzymes. The vector encodes a His-tagged protein containing residues 362-493 of the GyrA Vfi protein with the N-terminal sequence MGSSHHHHHHSSGLVPRGSHMT, where threonine corresponds to residue 362. The plasmids were transformed in E. coli K514 and the nucleotide sequence was checked by DNA sequencing. The sequence-verified plasmid was amplified, purified (QIAprep Spin Miniprep Kit, Qiagen, Valencia, CA, USA) and transformed in E. coli BL21(DE3) for expression. Expression and purification were performed analogously as for GyrA14 Ec (Dao-Thi et al., 2004) .
The C-terminal half of CcdA from E. coli plasmid F, CcdA F37-72 (amino-acid sequence NH 2 -RRLRAERWKAENQEGMAEVARF-IEMNGSFADENRDW-COOH), was synthesized by solid-phase synthesis by Bio-Synthesis, Lewisville, Texas, USA. The peptide was 99.14% pure as judged by HPLC analysis.
Preparation of the samples and crystallization
The CcdB Vfi sample was used at a concentration of 10 mg ml À1 in 20 mM Tris, 150 mM NaCl, 1 mM EDTA pH 7.0. The CcdB Vfi -GyrA14 Ec complex was prepared by adding concentrated CcdB Vfi (10 mg ml À1 ) to a diluted solution of GyrA14 Ec (2.8 mg ml À1 ). After a 1 h incubation time on ice, the complex was concentrated, purified with a Superdex 75 HR 10/30 column (Amersham Biosciences) and analyzed by SDS-PAGE. The sample was used at a concentration of 7 mg ml À1 in 50 mM Tris, 150 mM NaCl pH 7.5. The CcdB Vfi -GyrA14 Vfi complex was prepared in the same way as the CcdB Vfi -GyrA14 Ec complex. The CcdB Vfi -CcdAB F37-72 complex was prepared by mixing equal volumes of 3 mg ml À1 CcdB Vfi (20 mM Tris pH 7.0, 1 mM EDTA, 150 mM NaCl) and 2 mg ml À1 peptide (in water), followed by concentration to 10 mg ml À1 using a 0.5 kDa cutoff Vivaspin concentrator (Vivascience, Germany).
Initial screening of crystallization conditions was carried out with Crystal Screen, Crystal Screen II, Natrix Screen (Hampton Research) and Wizard Screen I (Emerald Biosystems) using the hanging-drop vapour-diffusion method at 293 K. Drops consisting of 2 ml protein solution and 2 ml precipitant solution were equilibrated against 500 ml precipitant solution. For the CcdB Vfi crystals, further optimization was carried out by varying the pH (7.0-8.0), protein concentration (8-10 mg ml À1 ) and precipitant concentration [30-36%(w/v)PEG 1000; 1.3-1.6 M LiSO 4 ]. Optimization was performed using the hanging-drop vapour-diffusion technique with the same drop and reservoir volumes as used in the initial screens, except for the optimization of the CcdB Vfi -GyrA14 Ec complex. In this case, optimization was performed in batch mode under paraffin oil, with drops consisting of 5 ml protein solution and 5 ml precipitant solution. The protein buffer, protein concentration and temperature remained the same as in the crystal screens for all optimization experiments.
Data collection
All crystals were flash-frozen directly in the nitrogen stream. Form 2 crystals of CcdB Vfi were cryoprotected by enriching the precipitant solution with 32.5%(v/v) glycerol, while for form 1 crystals no additional cryoprotectant was necessary. For the CcdB Vfi -GyrA14 Vfi complex crystals, precipitant solution enriched with 30%(v/v) glycerol was used. Crystals of the CcdB Vfi -GyrA14 Ec complex were transferred stepwise to precipitant solution enriched with 25%(v/v) glycerol using 5%(v/v) steps. Crystals of the CcdB Vfi -CcdA F37-72 complex were cryoprotected in precipitant solution with the PEG 4000 concentration raised to 40% via an intermediate 27.5% step. Data were collected at 100 K on EMBL beamlines X11, X13, BW7B at the DESY synchrotron (Hamburg, Germany) and on beamline ID14-2 at the ESRF synchrotron (Grenoble, France). All data were processed using the HKL package (Otwinowski & Minor, 1997) .
Results
Initial screening for crystals of CcdB Vfi resulted in several promising conditions. After optimization of the pH, protein concentration and the precipitant concentration, two conditions resulted in well diffracting crystals: condition 1 [50 mM Tris pH 7.0, 35%(w/v) PEG 400, 250 mM LiSO 4 ] and condition 2 [100 mM sodium citrate pH 5.6, 2%(v/v) polyethyleneimine, 500 mM NaCl]. Crystals observed in condition 1 look irregular in shape (with dimensions of 0.2 Â 0.2 Â 0.1 mm) and were found in drops that also contained phase separation and clusters of small needles ( Fig. 2a ). They diffracted to 1.5 Å resolution and belong to space group I23 or I2 1 3. The unit-cell parameter of a = 84.5 Å suggests a single subunit in the asymmetric unit, corresponding to a V M value of 2.93 Å 3 Da À1 . Crystals obtained from condition 2 appear as needles with secondary growth and with a maximal length of 0.6 mm (Fig. 2b) . They diffracted to 1.7 Å resolution and belong to space group C2, with unit-cell parameters a = 58.5, b = 43.6, c = 37.5 Å , = 110.0 . Again, the asymmetric unit consists of a single subunit (V M = 1.87 Å 3 Da À1 ). Further details of the data-collection statistics are given in Table 1 .
Initial screening for crystals of the CcdB Vfi -GyrA14 Ec complex resulted in crystals in several conditions, but the crystals were generally found to be quite fragile. Optimization of the pH (6.0-8.0) resulted in a data set for crystals grown in 50 mM MES pH 6.5, 1.6 M (NH 4 ) 2 SO 4 , 50 mM MgCl 2 . Several cryoprotectants were tested, but good diffraction was only observed with 25%(v/v) glycerol and only when the crystals were transferred in steps of 5%(v/v) glycerol. The crystals appeared as trapezium-shaped plates (0.2 Â 0.2 Â 0.02 mm; Fig. 2c ), diffracted to 1.95 Å resolution and belong to space group C2, with unit-cell parameters a = 130.1, b = 90.8, c = 58.1 Å , = 102.6 . The asymmetric unit is most likely to contain a dimer of complexes, with V M = 3.22 Å 3 Da À1 . The data-collection statistics are summarized in Table 1 .
Small crystals were also observed for the CcdB Vfi -GyrA14 Vfi complex in several conditions. Optimization (by changing the ratio of NaH 2 PO 4 and K 2 HPO 4 ) finally yielded the largest crystals in 1.2 M NaH 2 PO 4 , 0.8 M K 2 HPO 4 , 100 mM CAPS pH 10.0. These crystals appeared as plates with dimensions of 0.1 Â 0.1 Â 0.02 mm (see Fig. 2d ). They diffracted to 2.2 Å resolution and belong to space group P2 1 2 1 2 1 , with unit-cell parameters a = 53.5, b = 94.6, c = 58.1 Å The asymmetric unit contains one complex with V M = 2.93 Å 3 Da À1 . The data-collection statistics are given in Table 1 .
Diffraction-quality crystals of the Ccd Vfi -CcdA F37-72 complex were obtained directly from the screen [8%(w/v) PEG 4000, 0.1 M CH 3 COONaÁ3H 2 O pH 4.6]. They appeared as large bundles of needles with a length of 0.8 mm (see Fig. 2e ) and diffracted to 1.9 Å resolution. They belong to space group P2 1 2 1 2 1 , with unit-cell parameters a = 46.9, b = 62.6, c = 82.0 Å . The asymmetric unit consists of one, or more likely two, complexes with a V M of 5.01 or 2.5 Å 3 Da À1 , respectively. The data-collection statistics are listed in Table 1 .
For all the complexes, it was confirmed by molecular replacement that the complex was crystallized and not the free protein.
Discussion
We have crystallized for the first time a chromosomal homologue from the CcdB family of toxins, CcdB Vfi from V. fischeri. CcdB Vfi shows 41% sequence identity to F-plasmid CcdB F . Its two interaction partners, CcdA Vfi and GyrA Vfi , however, show 22% and 76% sequence identity to their respective F-plasmid and E. coli counterparts. This is surprising as CcdA and GyrA are two competing ligands for CcdB that cannot bind simultaneously (Bernard et al., 1993) . In addition, one of the crucial residues of F-plasmid CcdB F , Trp99, is not conserved in CcdB Vfi (Fig. 1) . The resulting crystal structures should thus provide further insights into how recognition and specificity is achieved in the CcdB protein family.
TA systems have recently been proposed as targets for the development of new antibiotics. For example, small molecules that can interrupt the binding between the toxin and its antitoxin or small molecules that mimic the activity of the toxin might lead to bacterial cell death DeNap & Hergenrother, 2005) . The structures derived from the crystals described here would help to validate such claims and aid the development of these potential small-molecule drugs. A comparison of the CcdB crystal structures of different origins and their complexes may allow the identification of the essential common elements in the CcdA-CcdB and CcdB-gyrase interactions, facilitating the development of broad host-range inhibitors.
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